Want to see SE:HNSA full AI Analyst Report?

Hansa Biopharma AB (HNSA) Price & Analysis

18 Followers

HNSA Stock Chart & Stats

kr43.30

-kr1.84(-4.67%)

At close: Jul 27 4:00 PM EDT

kr43.30

-kr1.84(-4.67%)

Day’s Range― - ―

52-Week Rangekr23.52 - kr48.22

Previous CloseN/A

Volume1.15M

Average Volume (3M)509.20K

Market Cap

kr3.89B

Enterprise Valuekr4.01B

Total Cash (Recent Filing)kr552.81M

Total Debt (Recent Filing)kr1.03B

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Nov 05, 2026

EPS Estimate

6.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-7.86

Shares Outstanding101,763,220

10 Day Avg. Volume334,431

30 Day Avg. Volume509,198

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)-31.35

Price to Sales (P/S)12.55

P/FCF Ratio-5.08

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr103.00

Price Target Upside137.88% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)1.03

Revenue Forecast (FY)kr467.54M

Bulls Say, Bears Say

Bulls Say

SERB Partnership Strengthens LiquidityThe SERB transaction provides substantial near-term funding and extends the company’s runway ahead of potential U.S. approval. It also validates the platform commercially, adds a regional commercialization partner, and can reduce financing pressure while Hansa advances its own pipeline.

Strong Confirmatory Clinical EfficacyPositive confirmatory data strengthens imlifidase’s clinical and regulatory foundation by demonstrating better kidney function and reduced dialysis dependence versus control. This supports European approval conversion, physician confidence, and the durability of the lead product’s commercial opportunity.

U.S. Launch And Regulatory ReadinessA defined U.S. regulatory milestone, active center preparation, and planned market-access work create a clear path toward geographic expansion. Approval could broaden Idefirix’s commercial reach beyond Europe and improve the company’s ability to scale revenue from a specialized transplant indication.

Bears Say

Sharp Revenue Decline And Deep LossesThe sharp TTM revenue contraction shows that the existing commercial base has not yet produced reliable scale. Extremely negative profitability means product-level gross margin is being outweighed by operating costs, leaving the business dependent on future growth, partnerships, or external funding.

Negative Equity And Persistent Cash BurnNegative equity combined with substantial debt reduces financial flexibility and increases sensitivity to continued losses. Persistent operating and free-cash-flow deficits indicate that the company is consuming cash to fund operations, making the recently strengthened liquidity important but not a complete solution.

Higher Antibody-mediated Rejection RateThe higher observed AMR rate remains a clinically meaningful consideration for physicians, regulators, and transplant centers even though management described events as manageable and reported no graft losses. Continued monitoring and treatment could complicate adoption and limit confidence in broader use.

Hansa Biopharma AB News

Hansa Biopharma’s Idefirix PAES Study Earns High-Impact Spotlight at ASN Kidney Week

Hansa Biopharma AB ( ($SE:HNSA) ) just unveiled an announcement. Hansa Biopharma said the European Post-Authorization Efficacy and...

2d ago

Hansa Biopharma Files IND with FDA for Novel GBS Therapy HNSA-5487

Hansa Biopharma AB ( ($SE:HNSA) ) has shared an update. Hansa Biopharma has submitted an Investigational New Drug...

2d ago

Hansa Biopharma leadership to highlight kidney transplant focus at U.S. virtual forum

Hansa Biopharma AB ( ($SE:HNSA) ) has shared an announcement. Hansa Biopharma AB, a Lund-based biopharmaceutical company specializing...

9d ago

Hansa Biopharma CEO to Join Industry Panel at Biotech in Europe Forum

Hansa Biopharma AB ( ($SE:HNSA) ) has issued an announcement. Hansa Biopharma’s chief executive, Renée Aguiar-Lucander, is set...

20d ago

Hansa Biopharma Taps Cradle’s AI Platform to Speed Autoimmune Drug Discovery

The latest announcement is out from Hansa Biopharma AB ( ($SE:HNSA) ). Hansa Biopharma has entered into a...

21d ago

Hansa Biopharma Adds Commercial and Financial Heavyweights to Board

An update from Hansa Biopharma AB ( ($SE:HNSA) ) is now available. Hansa Biopharma has strengthened its board...

28d ago

Hansa Biopharma Adds New Directors and Adopts Long-Term RSU Program at Extraordinary Meeting

Hansa Biopharma AB ( ($SE:HNSA) ) just unveiled an update. Hansa Biopharma AB held an Extraordinary General Meeting...

30d ago

Hansa Biopharma Joins Global Expansion Panel at LSX Congress USA

Hansa Biopharma AB ( ($SE:HNSA) ) just unveiled an update. Hansa Biopharma will participate in the LSX Congress...

1M ago

Hansa Biopharma CEO to Present at Pareto Securities’ 2026 Healthcare Conference

Hansa Biopharma AB ( ($SE:HNSA) ) has issued an announcement. Hansa Biopharma will showcase its strategy and pipeline...

2M ago

Hansa Biopharma Calls Extraordinary Meeting to Reshape Board and Governance

The latest announcement is out from Hansa Biopharma AB ( ($SE:HNSA) ). Hansa Biopharma has called an Extraordinary...

2M ago

Hansa Biopharma initiated with a Buy at Danske Bank

Danske Bank initiated coverage of Hansa Biopharma (HNSBF) with a Buy rating and SEK 53 price target The...

4M ago

Hansa Biopharma price target lowered to SEK 103 from SEK 111 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Hansa Biopharma (HNSBF) to SEK 103 from...

8M ago

Hansa Biopharma initiated with an Outperform at Wedbush

Wedbush initiated coverage of Hansa Biopharma (HNSBF) with an Outperform rating and SEK 69 price target The firm...

10M ago

Hansa Biopharma price target lowered to SEK 111 from SEK 132 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Hansa Biopharma (HNSBF) to SEK 111 from SEK 132 and...

10M ago

HNSA FAQ

What was Hansa Biopharma AB’s price range in the past 12 months?

Hansa Biopharma AB lowest stock price was kr23.52 and its highest was kr48.22 in the past 12 months.

What is Hansa Biopharma AB’s market cap?

Hansa Biopharma AB’s market cap is kr3.89B.

When is Hansa Biopharma AB’s upcoming earnings report date?

Hansa Biopharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.

How were Hansa Biopharma AB’s earnings last quarter?

Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -kr2.56 earnings per share for the quarter, missing the consensus estimate of -kr0.337 by -kr2.223.

Is Hansa Biopharma AB overvalued?

According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hansa Biopharma AB pay dividends?

Hansa Biopharma AB does not currently pay dividends.

What is Hansa Biopharma AB’s EPS estimate?

Hansa Biopharma AB’s EPS estimate is 6.12.

How many shares outstanding does Hansa Biopharma AB have?

Hansa Biopharma AB has 101,763,220 shares outstanding.

What happened to Hansa Biopharma AB’s price movement after its last earnings report?

Hansa Biopharma AB reported an EPS of -kr2.56 in its last earnings report, missing expectations of -kr0.337. Following the earnings report the stock price went down -3.895%.

Which hedge fund is a major shareholder of Hansa Biopharma AB?

Currently, no hedge funds are holding shares in SE:HNSA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Hansa Biopharma AB

Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.

Hansa Biopharma AB (HNSA) Earnings & Revenues

Historic Earnings Reports

HNSA Stock 12 Month Forecast

Average Price Target

kr103.00

▲(137.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"kr26","65":"kr65","104":"kr104","45.5":"kr45.5","84.5":"kr84.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr103.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr103.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr103.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,45.5,65,84.5,104],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.12,39.418461538461536,44.716923076923074,50.01538461538461,55.31384615384615,60.61230769230769,65.91076923076923,71.20923076923077,76.50769230769231,81.80615384615385,87.10461538461539,92.40307692307692,97.70153846153846,{"y":103,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.12,39.418461538461536,44.716923076923074,50.01538461538461,55.31384615384615,60.61230769230769,65.91076923076923,71.20923076923077,76.50769230769231,81.80615384615385,87.10461538461539,92.40307692307692,97.70153846153846,{"y":103,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.12,39.418461538461536,44.716923076923074,50.01538461538461,55.31384615384615,60.61230769230769,65.91076923076923,71.20923076923077,76.50769230769231,81.80615384615385,87.10461538461539,92.40307692307692,97.70153846153846,{"y":103,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.74,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.26,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.62,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.1,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.78,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.12,"date":1790812800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >